Literature DB >> 25197413

Synchronous uterine carcinosarcoma and contralateral breast cancer after tamoxifen therapy: a case report.

Ling Shen1, Liangli Hong2, Guohong Zhang3, Ruiqin Mai4.   

Abstract

Uterine carcinosarcoma (malignant mixed Müllerian tumor, MMMT) is a rare aggressive malignant tumor, which demonstrates both malignant epithelial (carcinoma) and mesenchymal (sarcoma) components. Synchronous uterine carcinosarcoma and contralateral breast cancer in patient received tamoxifen treatment had not been reported. We present a case of uterine carcinosarcoma co-occurrenced with contralateral breast cancer in a 56-year-old nulliparous, obese breast cancer patient, who had been treated with tamoxifen for 5 years. The patient presented with palpable pelvic mass and vaginal bleeding. Histopathological evidence revealed that the tumor was comprised of an admixture of malignant epithelial and mesenchymal components. The epithelial component was endometrioid type adenocarcinoma, while sarcomatous component had heterologous elements including fusiform cell sarcoma and a prominent component of cartilage. The infiltrating ductal carcinoma has been diagnosed on her right breast. The patient died of disease 8 months after diagnosis. Postmenopausal patients, with adjuvant tamoxifen treatment for breast cancer, are at increased risk for the development of uterine carcinosarcoma and less benefit for contralateral breast cancer.

Entities:  

Keywords:  Uterine carcinosarcoma; contralateral breast cancer; tamoxifen

Mesh:

Substances:

Year:  2014        PMID: 25197413      PMCID: PMC4152103     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  23 in total

1.  A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma.

Authors:  Leigh A Cantrell; Laura Havrilesky; Dominic T Moore; David O'Malley; Margaret Liotta; Angeles Alvarez Secord; Christa I Nagel; David E Cohn; Amanda Nickles Fader; Amy H Wallace; Peter Rose; Paola A Gehrig
Journal:  Gynecol Oncol       Date:  2012-06-20       Impact factor: 5.482

2.  Fatty liver and transaminase changes with adjuvant tamoxifen therapy.

Authors:  Chien-Liang Liu; Jon-Kway Huang; Shih-Ping Cheng; Yuan-Ching Chang; Jie-Jen Lee; Tsang-Pai Liu
Journal:  Anticancer Drugs       Date:  2006-07       Impact factor: 2.248

Review 3.  Epidemiology of contralateral breast cancer.

Authors:  Y Chen; W Thompson; R Semenciw; Y Mao
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1999-10       Impact factor: 4.254

4.  Toremifene-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment.

Authors:  N Hamada; Y Ogawa; T Saibara; Y Murata; S Kariya; A Nishioka; M Terashima; T Inomata; S Yoshida
Journal:  Int J Oncol       Date:  2000-12       Impact factor: 5.650

5.  Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study.

Authors:  Howard D Homesley; Virginia Filiaci; Maurie Markman; Pincas Bitterman; Lynne Eaton; Larry C Kilgore; Bradley J Monk; Frederick R Ueland
Journal:  J Clin Oncol       Date:  2007-02-10       Impact factor: 44.544

6.  Adjuvant hormonal therapy for breast cancer and risk of hormone receptor-specific subtypes of contralateral breast cancer.

Authors:  Christopher I Li; Janet R Daling; Peggy L Porter; Mei-Tzu C Tang; Kathleen E Malone
Journal:  Cancer Res       Date:  2009-08-25       Impact factor: 12.701

Review 7.  Tamoxifen-related uterine carcinosarcomas occur under/after prolonged treatment: report of five cases and review of the literature.

Authors:  I Kloos; S Delaloge; P Pautier; M Di Palma; A Goupil; P Duvillard; P E Cailleux; C Lhomme
Journal:  Int J Gynecol Cancer       Date:  2002 Sep-Oct       Impact factor: 3.437

8.  Why are reproductive cancers more common in nulliparous women?

Authors:  Norbert Gleicher
Journal:  Reprod Biomed Online       Date:  2013-01-29       Impact factor: 3.828

9.  Uterine carcinosarcomas (malignant mixed müllerian tumours): a review with special emphasis on the controversies in management.

Authors:  Rani Kanthan; Jenna-Lynn Senger
Journal:  Obstet Gynecol Int       Date:  2011-10-05

10.  Joint effects of nulliparity and other breast cancer risk factors.

Authors:  S Opdahl; M D K Alsaker; I Janszky; P R Romundstad; L J Vatten
Journal:  Br J Cancer       Date:  2011-08-02       Impact factor: 7.640

View more
  2 in total

1.  Mutational landscape implicates epithelial-mesenchymal transition gene TGF-β2 mutations for uterine carcinosarcoma after adjuvant tamoxifen therapy for breast carcinoma.

Authors:  Ling Shen; Liangli Hong; Songxia Zhou; Guohong Zhang; Ruiqin Mai
Journal:  Int J Clin Exp Pathol       Date:  2019-03-01

2.  A Case of Uterine Carcinosarcoma Detected Simultaneously with Breast and Colon Cancer (Triple Primary Malignant Tumor).

Authors:  Eunhyun Lee; Yong-Il Ji
Journal:  Case Rep Oncol       Date:  2018-06-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.